12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xilonix: Interim Phase II data

Interim data from 42 evaluable patients undergoing percutaneous revascularization of the superficial femoral artery in an open-label, U.S. Phase II trial showed that MABp1 plus standard of care (SOC) led to a 58% reduction in the incidence of MACE vs. SOC alone. Additionally, patients...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >